A recent study by a group of researchers from the University of British Columbia has found that the composition of meconium can be used to find out whether a baby will develop allergies as they get older. Meconium, which is a child’s first poop, is a thick dark-green substance. The research was reported in the Cell Reports Medicine journal.
Dr. Brett Finlay, a professor from the university’s departments of immunology, microbiology, molecular biology and biochemistry, explained that the analysis they conducted showed that compared with babies who didn’t develop allergic sensitization, those who did had considerably less rich meconium after they were born. Finlay was also the senior co-author of the study.
Meconium contains various materials that are ingested and excreted during development, which range from molecules called metabolites, amniotic fluid and skin cells and is usually passed within the first day of a baby being born. A research associate from the university’s department of pediatrics, Dr. Charisse Petersen, who was also the lead author of the study, noted that meconium revealed what a child had been exposed to before they were born as it is made up of molecules the infant encountered in the womb.
For their research, the scientists examined meconium samples obtained from 100 babies who were part of the CHILD cohort study. The study conducts child, newborn and maternal health research. The researchers found that the infant’s risk of developing allergies by the time they were one increased if they had fewer types of molecules in their meconium. They also discovered that a decrease in specific molecules was linked to changes in major bacterial groups. These groups play a crucial role in the maturation and development of an extensive system of microbiota, which plays a critical role in health and disease.
The researchers also used a machine-learning algorithm to combine clinical data, microbe and meconium to reliably forecast whether a baby would develop allergies by the time they were aged one. They noted that the findings had key implications for babies who were at risk.
Petersen noted that their study demonstrated that the development of microbiota and a healthy immune system could probably begin even before an infant was born, which shows that the molecules a baby is exposed to in the womb played an important role in future health.
Dr. Stuart Turvey, the senior co-author of the study, asserted that it would become easier to identify babies who were at risk, noting that infants who had allergies had the highest risk of also developing asthma and would benefit from early interventions before they began displaying symptoms and signs of asthma or allergies when they were older.
Any early interventions made to avert allergies and other potential health risks from developing in babies would ease the pressure on the solutions or resources companies such as United Medical Equipment Business Solutions Network Inc. avail to vulnerable members of society, such as the elderly.
NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.